Roles of the Skp2/p27 axis in the progression of chronic nephropathy

Cellular and Molecular Life Sciences

Volumn 70, Issue 18, 2013, Pages 3277-3287

  Suzuki, Sayuri ^a   Ohashi, Naro ^a   Kitagawa, Masatoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic nephropathy; p27; Skp2; Ubiquitin ligase; Ubiquitin proteasome

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P21; PROTEIN P27; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SMAD PROTEIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

CELL CYCLE REGULATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; KIDNEY INJURY; KIDNEY TUBULE CELL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; URETER OBSTRUCTION;

ANIMALS; CELL CYCLE; CHRONIC DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MICE; MICE, TRANSGENIC; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; THYMOCYTES; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN-PROTEIN LIGASES; URETERAL OBSTRUCTION;

MUS;

EID: 84883450407     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-1232-x     Document Type: Review

References (122)

1. Morgan DO (1995) Principles of CDK regulation. Nature 374:131-134
2. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163
3. Nourse J, Firpo E, Flanagan WM et al (1994) Interlukin-2-mediated elimination of the p27kip1 cyclin-dependent kinases inhibitor prevented by rapamycin. Nature 372:570-573
4. Polyak K, Lee MH, Erdjument-Bromage H et al (1994) Cloning of p27kip1, a cyclin-dependent kinases inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78:59-66
5. Weissman AM (1997) Regulating protein degradation by ubiquitination. Immunol Today 18:189-198
6. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479
7. Carrano AC, Eytan E, Hershko A et al (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199
8. Tsvetkov LM, Yeh KH, Lee SJ et al (1999) p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9:661-664
9. Spruck C, Strohmaier H, Watson M et al (2001) A CDK-independent function of mammalian Cks1: targeting of SCF (Skp2) to the CDK inhibitor p27Kip1. Mol Cell 7:639-650
10. Ganoth D, Bornstein G, Ko TK et al (2001) The cell-cycle regulatory protein Cks1 is required for SCF-Skp2-mediated ubiquitinylation of p27. Nat Cell Biol 3:321-324
11. Nakayama K, Nagahama H, Minamishima YA et al (2000) Targeted disruption of Skp2 results in accumulation of cyclin E and p27kip1, polyploidy and centrosome overduplication. EMBO J 19(9):2069-2081
12. Couser WG, Johnson RJ (1994) Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 23:193-198
13. Gobe GC, Axelsen RA (1987) Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab Invest 56:273-281
14. Walton G, Buttyan R, Garcia Montes E et al (1992) Renal growth factor expression during the early phase of experimental hydronephrosis. J Urol 148:510-514
15. Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283:F861-F875
16. Fukasawa H, Yamamoto T, Togawa A et al (2006) Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int 69:1733-1740
17. Schreiner GF, Harris KP, Purkerson ML et al (1988) Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int 34(4):487-493
18. Ricardo SD, Levinson ME, DeJoseph MR et al (1996) Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney Int 50(6):2002-2010
19. Chevalier RL, Forbes MS, Thornhill BA et al (2009) Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75:1145-1152
20. Suzuki S, Fukasawa H, Kitagawa K et al (2007) Renal damage in obstructive nephropathy is decreased in Skp2-deficient mice. Am J Pathol 171(2):473-483
21. Misaki T, Yamamoto T, Suzuki S et al (2009) Decrease in tumor necrosis factor-alpha receptor-associated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats. Am J Pathol 175(1):74-83
22. Yamashita S, Maeshima A, Nojima Y (2005) Involvement of renal progenitor tubular cells in epithelial-to-mesenchymal transition in fibrotic rat kidneys. J Am Soc Nephrol 16(7):2044-2051
23. Liu Y (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15(1):1-12
24. Fukasawa H, Fujigaki Y, Yamamato T et al (2012) Protein degradation by the ubiquitin-proteasome pathway and organ fibrosis. Curr Med Chem 19:893-900
25. Yamamoto T, Noble NA, Miller DE et al (1994) Sustained expression of TGF-beta1 underlies development of progressive kidney fibrosis. Kidney Int 45:916-927
26. Watanabe T, Yamamoto T, Ikegaya N et al (2002) Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephropathy in rats. J Pathol 198(3):397-406
27. Fukasawa H, Yamamoto T, Suzuki H et al (2004) Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 65:63-74
28. Ng YY, Huang TP, Yang WC (1998) Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54(3):864-876
29. Sinuani I, Weissgarten J, Beberashvili I et al (2009) The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrol Dial Transplant 24(8):2328-3238
30. Wolf G, Schroeder R, Thaiss F et al (1998) Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 53(4):869-879
31. Awazu M, Omori S, Ishikura K et al (2003) The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 14(3):699-708
32. Border WA, Ruoslahti E (1992) Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 90:1-7
33. Eddy AA (1996) Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508
34. Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292
35. Okada H, Danoff TM, Kalluri R et al (1997) Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273:F563-F574
36. Fan JM, Ng YY, Hill PA et al (1999) Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 56:1455-1467
37. Robert LC (2006) Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2:157-168
38. García-Sánchez O, López-Hernández FJ, López-Novoa JM (2010) An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 77(11):950-955
39. Yu L, Hébert MC, Zhang YE (2002) TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 21(14):3749-3759
40. Dai C, Yang J, Liu Y (2003) Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 278(14):12537-12545
41. Ohashi N, Yamamoto T, Uchida C et al (2005) Transcriptional induction of Smurf2 ubiquitin ligase by TGF-β. FEBS Lett 579:2557-2563
42. Fukasawa H, Yamamato T, Kitagawa M et al (2008) Regulation of TGF-beta signaling by Smads and its roles in tissue fibrosis. Curr Signal Trunsduct Ther 3:1-6
43. Böttinger EP, Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13:2600-2610
44. Lin H, Wang D, Wu T et al (2011) Blocking core fucosylation of TGF-β1 receptors downregulates their functions and attenuates the epithelial-mesenchymal transition of renal tubular cells. Am J Physiol Renal Physiol 300:F1017-F1025
45. Derynck R, Zhang Y, Feng XH (1998) Smads: transcriptional activators of TGF-beta responses. Cell 95(6):737-740
46. Togawa A, Yamamoto T, Suzuki H et al (2003) Ubiquitin-dependent degradation of Smad2 is increased in the glomeruli of rats with anti-thymocyte serum nephritis. Am J Pathol 163(4):1645-1652
47. Wang W, Koka V, Lan HY (2005) Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology 10(1):48-56
48. Fukasawa H, Yamamoto T, Togawa A et al (2004) Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 101(23):8687-8692
49. Oh SP, Seki T, Goss KA et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. PNAS 97:2626-2631
50. Wang W, Ungermannova D, Jin J et al (2004) Negative regulation of SCFSkp2 ubiquitin ligase by TGF-beta signaling. Oncogene 23(5):1064-1075
51. Liu W, Wu G, Li W et al (2007) Cdh1-anaphase-promoting complex targets Skp2 for destruction in transforming growth factor beta-induced growth inhibition. MCB 27(8):2967-2979
52. Hu D, Liu W, Wu G et al (2011) Nuclear translocation of Skp2 facilitates its destruction in response to TGFβ signaling. Cell Cycle 10(2):285-292
53. He KL, Ting AT (2002) A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol Cell Biol 22:6034-6045
54. Misseri R, Meldrum DR, Dinarello CA et al (2005) TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol Renal Physiol 288:F406-F411
55. Meldrum KK, Metcalfe P, Leslie JA et al (2006) TNF-alpha neutralization decreases nuclear factor-kappaB activation and apoptosis during renal obstruction. J Surg Res 13:182-188
56. Meldrum KK, Misseri R, Metcalfe P et al (2007) TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis. Am J Physiol Regul Integr Comp Physiol 292:1456-1464
57. Ramesh G, Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-F618
58. Bharat BA (2003) Signaling pathways of the superfamily: a double-edged sword. Immunology 3:745-756
59. Gioacchino N, Liv MIA (2008) A birthday gift for TRADD. Nat Immunol 9(9):1015-1016
60. Wang D, Montgomery RB, Schmidt LJ et al (2009) Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res 69(24):9448-9456
61. Hsu H, Shu HB, Pan MG et al (1996) TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308
62. Rothe M, Sarma V, Dixit VM et al (1995) TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 269:1424-1427
63. Guo G, Morrissey J, McCracken R et al (1999) Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277:F766-F772
64. Weiss T, Grell M, Siemienski K et al (1998) TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol 161(6):3136-3142
65. Mukhopadhyay A, Suttles J, Stout RD et al (2001) Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 276(34):31906-31912
66. Collins T (1993) Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 68(5):499-508
67. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179
68. Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory disease. J Clin Invest 107:7-11
69. Ruiz-Ortega M, Bustos C, Hernández-Presa MA (1998) Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161(1):430-439
70. Pocock J, Gómez-Guerrer C, Harendza S et al (2003) Differential activation of NF-κB, AP-1, and C/EBP in endotoxin-tolerant rats: mechanisms for in vivo regulation of glomerular RANTES/CCL5 expression. J Immunol 170(12):6280-6291
71. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 1:2195-2224
72. Cao Y, Bonizzi G, Seagroves TN et al (2001) IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107:763-775
73. Morrissey JJ, Klahr S (1997) Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 52(4):926-933
74. Schneider G, Saur D, Siveke JT et al (2006) IKK alpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression. EMBO J 25:3801-3812
75. Barré B, Perkins ND (2010) The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol Cell 38:524-538
76. Suzuki S, Fukasawa H, Misaki T et al (2011) Up-regulation of Cks1 and Skp2 with TNFα/NF-κB signaling in chronic progressive nephropathy. Genes Cells 16(11):1110-1120
77. Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438-449
78. Sutterlüty H, Chatelain E, Marti A et al (1999) p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1:207-214
79. Kamura T, Hara T, Matsumoto M et al (2004) Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 6:1229-1235
80. Kip1. Cancer Res 67:10789-10795
81. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501-1512
82. Elledge SJ, Winston J, Harper JW (1996) A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol 6(10):388-392
83. kip1 for restriction point control of the fibroblast cell cycle. Science 272:877-880
84. kip1. Kidney Int 51:1088-1099
85. Loda M, Cukor B, Tam SW et al (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3(2):231-234
86. Esposito V, Baldi A, De Luca A et al (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57(16):3381-3385
87. Steeg PS, Abrams JS (1997) Cancer prognostics: past, present and p27. Nat Med 3(2):152-154
88. KIP1 after unilateral ureteral obstruction is independent of angiotensin II. Kidney Int 61:68-79
89. Schaefer L, Macakova K, Raslik L et al (2002) Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160(3):1181-1191
90. kip1 safeguards against inflammatory injury. Nat Med 4:575-580
91. Hughes J, Brown P, Shankland SJ (1999) Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial cell proliferation following ureteric obstruction. Am J Physiol 277:F948-F956
92. Pujols L, Fernández-Bertolín L, Fuentes-Prado M et al (2012) Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts. J Pharmacol Exp Ther 343(1):184-197
93. Zhou H, Kato A, Yasuda H et al (2004) The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure. Toxicol Appl Pharmacol 200(2):111-120
94. Ibrahim HN, Hostetter TH (1997) Diabetic nephropathy. J Am Soc Nephrol 8(3):487-493
95. Chiara M, Menegatti E, Di Simone D et al (2004) Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis. Clin Exp Immunol 139(2):225-235
96. Shankland SJ, Hugo C, Coats SR (1996) Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 50(4):1230-1239
97. -/- mice. PLoS One 7(4):e36249
98. Li R, Waga S, Hannon GJ et al (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537
99. Chen J, Jackson PK, Kirschner MW et al (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388
100. Bornstein G, Bloom J, Sitry-Shevah D et al (2003) Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278(28):25752-25757
101. Sheaff RJ, Singer JD, Swanger J et al (2000) Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 5(2):403-410
102. Morrissey JJ, Ishidoya S, McCrachen R et al (1996) Control of p53 and p21 (WAF1) expression during unilateral ureteral obstruction. Kidney Int Suppl 57:S84-S92
103. Megyesi J, Udvarhelyi N, Safirstein RL et al (1996) The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol 271:F1211-F1216
104. Zhou H, Fujigaki Y, Kato A et al (2006) Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats. Am J Physiol Renal Physiol 291(1):F225-F235
105. Waga S, Hannon GJ, Beach D et al (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578
106. 1 arrest and apoptosis. Cancer Res 54(5):1169-1174
107. Kuan CJ, al-Douahji M, Shankland SJ (1998) The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9(6):986-993
108. Kim YG, Alpers CE, Brugarolas J et al (1999) The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 55(6):2349-2361
109. Lee MH, Reynisdóttir I, Massagué J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9(6):639-649
110. Matsuoka S, Edwards MC, Bai C et al (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9(6):650-662
111. Zhang P, Wong C, DePinho RA (1998) Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev 12(20):3162-3167
112. Lovicu FJ, McAvoy JW (1999) Spatial and temporal expression of p57(KIP2) during murine lens development. Mech Dev 86(1-2):165-169
113. Nagata M, Nakayama K, Terada Y et al (1998) Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 153(5):1511-1520
114. Shankland SJ, Eitner F, Hudkins KL et al (2000) Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 58(2):674-683
115. Hiromura K, Haseley LA, Zhang P et al (2001) Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 60(6):2235-2246
116. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828
117. El-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75(4):817-825
118. Smith ML, Chen IT, Zhan Q et al (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380
119. Choi YJ, Mendoza L, Rha SJ et al (2001) Role of p53-dependent activation of caspases in chronic obstructive uropathy: evidence from p53 null mutant mice. J Am Soc Nephrol 12(5):983-992
120. Tashiro K, Tamada S, Kuwabara N et al (2003) Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med 12:587-592
121. Neubert K, Meister S, Moser K et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14:748-755
122. Huber JM, Tagwerker A, Heininger D et al (2009) The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 297:F451-F460